Bausch + Lomb Corporation
BLCO
Jodie situation report
Bausch + Lomb Corporation's current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 15 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- Revenue increased 9.4% versus the comparable filing period.
- BLCO's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if BLCO's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind BLCO
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
WMTWalmart Inc.distributorFeb 18, 2026 ▾
“Distribution Fees The Company sells products to certain wholesalers, and large pharmacy chains such as CVS and Walmart, usually under Distribution Services Agreements ("DSAs").”
NVSNovartis AGinvesteeFeb 18, 2026 ▾
“2023 Acquisitions Acquisition of XIIDRA ® On June 30, 2023, a wholly owned subsidiary of the Company, Bausch + Lomb Ireland Limited, entered into a Stock and Asset Purchase Agreement (the “Acquisition Agreement”) with Novartis Pharma AG and Novartis Finance C…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
BLCO is currently a Early Follower in the organic co-movement group Drug Manufacturers - General. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.